Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2021-10-26 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding the non-applicability of certain regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically related to Beta Drugs Limited being listed on the SME Exchange. It discusses regulatory compliance and disclosure exemptions rather than presenting financial data, audit results, or management information. The document is short (1945 characters) and serves as a regulatory notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-10-26 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on 25th October 2021 by Beta Drugs Limited. It includes approval of unaudited standalone and consolidated financial results for the half year ended 30th September 2021, along with a limited review report by auditors. The document contains substantive financial data such as revenue, expenses, profit before tax, and other financial metrics for the half year period. The presence of unaudited consolidated financial results and the limited review report indicates this is an Interim / Quarterly Report. The document is about half-year financial results, which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, but contains actual financial statements and analysis. Therefore, the correct classification is IR with high confidence.
2021-10-25 English
Financial Results Updates
Regulatory Filings
2021-10-25 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on 25th October 2021 by Beta Drugs Limited. It includes approval of unaudited standalone and consolidated financial results for the half year ended 30th September 2021, along with a limited review report by auditors. The document contains substantive financial data such as revenue, expenses, profit before tax, and other financial metrics for the half year period. The presence of unaudited consolidated financial results and detailed financial statements for the half year period indicates this is an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, but contains actual financial data and analysis for a period shorter than a full fiscal year. Therefore, the correct classification is Interim / Quarterly Report (IR).
2021-10-25 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification about a forthcoming Board Meeting scheduled for 25th October 2021. It specifically mentions that the agenda includes consideration and approval of unaudited standalone and consolidated financial results for the half year ended 30th September 2021. The document is an intimation to the stock exchange as per SEBI regulations, indicating it is an announcement of a meeting rather than the financial results report itself. The document length is short (1176 characters), and it does not contain any financial data or detailed analysis. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) notifying about the board meeting and upcoming financial results approval.
2021-10-13 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued by Link Intime India Pvt. Ltd., a registrar and transfer agent, regarding compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. It confirms the processing of dematerialisation requests for securities during the quarter ended 30th September 2021, including acceptance/rejection and cancellation of certificates. The document is a compliance certificate related to securities processing and does not contain financial statements, management discussion, or detailed report content. It is not an announcement of a report but a regulatory compliance confirmation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2021-10-11 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.